Literature DB >> 17051245

Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation.

C Karlsson, S Norin, E Kimby, B Sander, A Porwit Macdonald, B Nilsson, E Johansson, H Mellstedt, J Lundin, A Osterborg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17051245     DOI： 10.1038/sj.leu.2404435

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  7 in total

Review 1.  Eradication of minimal residual disease in chronic lymphocytic leukemia.

Authors:  Carmen Diana Schweighofer; Michael Hallek; Clemens-Martin Wendtner
Journal:  Curr Hematol Malig Rep       Date:  2008-01       Impact factor: 3.952

Review 2.  How I treat CLL up front.

Authors:  John G Gribben
Journal:  Blood       Date:  2009-10-22       Impact factor: 22.113

3.  How we treat Richter syndrome.

Authors:  Sameer A Parikh; Neil E Kay; Tait D Shanafelt
Journal:  Blood       Date:  2014-01-13       Impact factor: 22.113

4.  First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab.

Authors:  Carmen Diana Schweighofer; Clemens-Martin Wendtner
Journal:  Onco Targets Ther       Date:  2010-06-24       Impact factor: 4.147

5.  Severe, refractory, non-malignant type I cryoglobulinemia treated with alemtuzumab.

Authors:  David Chu; Michelle Stevens; Douglas Edward Gladstone
Journal:  Rheumatol Int       Date:  2007-04-19       Impact factor: 2.631

Review 6.  Alemtuzumab for patients with chronic lymphocytic leukaemia.

Authors:  Nicole Skoetz; Kathrin Bauer; Thomas Elter; Ina Monsef; Verena Roloff; Michael Hallek; Andreas Engert
Journal:  Cochrane Database Syst Rev       Date:  2012-02-15

7.  Alemtuzumab in chronic lymphocytic leukemia.

Authors:  G Fraser; C A Smith; K Imrie; R Meyer
Journal:  Curr Oncol       Date:  2007-06       Impact factor: 3.677
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.